Neurocrine Biosciences (NBIX) Misses Q3 EPS by 8c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Neurocrine Biosciences Reports Third Quarter 2019 Financial Results
November 4, 2019 4:01 PM ESTSAN DIEGO, Nov. 4, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended September 30, 2019 and provided an update on the launch of INGREZZA® (valbenazine) and its clinical development programs.
"We are pleased that a record number of new patients initiated treatment with INGREZZA as healthcare providers continue... More
